Keylika

2 employees

Keylika developed a platform synthesis technology that is used to generate multitude of organometallic drugs.

Basic info

biotechnology research

platform synthesis technology

transdermal patch

Bioinorganic drugs

Iron deficiency anemia

IDA

drug development

drug delivery

Clinical Trials

first principles design

organometallic drugs

transdermal

formulation

Medical

2022

Keylika raised undisclosed on August 22, 2022

Investors: Y Combinator